Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral LPM526000133 Fumarate Capsules (LY03017) in Healthy Adult Subjects.
NCT06980207 is registered in ClinicalTrials.gov with Luye Pharma Group Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral LPM526000133 Fumarate Capsules (LY03017) in Healthy Adult Subjects.
- Lead sponsor
- Luye Pharma Group Ltd.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- May 31, 2025
- Completion date
- October 31, 2025
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hallucinations and delusions associated with alzheimer's disease psychosis, hallucinations and delusions associated with parkinson disease psychosis, negative symptoms of schizophrenia